Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer
NCT01861054
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
20
Enrollment
INDUSTRY
Sponsor class
Stopped
Enrollment target not reached
Conditions
Breast Cancer
Interventions
DRUG:
Reparixin
Sponsor
Dompé Farmaceutici S.p.A